AstraZeneca has announced a three-year research collaboration with the French National Institute of Health and Medical Research (Inserm) to investigate new therapeutic approaches to type 2 diabetes and chronic kidney disease (CKD). The aim of the collaboration is to advance understanding of the biological mechanisms that underpin these conditions and develop new treatments based on this knowledge.
Each project will comprise a joint team of investigators that will work across Inserm sites in Toulouse and Paris, and AstraZeneca’s research hub in Mölndal, Sweden. The collaboration will focus on three areas:
Understanding mineralocorticoid receptor activity as a route to treating CKD
